purchaser. The interchangeable [~~biosimilar~~] biological product container shall be labeled with the name of the interchangeable [~~biosimilar~~] biological product dispensed, and the pharmacist, pharmacy intern, or pharmacy technician shall indicate on the file copy of the prescription both the name of the prescribed biological product and the name of the interchangeable [~~biosimilar~~] biological product dispensed in its place.

[~~(8) (a) A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar product for a prescribed biological product shall:~~]

[~~(i) notify the prescriber in writing, by fax, telephone, or electronic transmission of the substitution, as soon as practicable, but not later than three business days after dispensing the interchangeable biosimilar product in place of the prescribed biological product; and~~]

[~~(ii) include the name and manufacturer of the interchangeable biosimilar product substituted.~~]

[~~(b) This subsection is repealed on May 15, 2015.~~]

(8) Within five business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee shall make an entry of the specific product provided to the patient, including the name of the product and the manufacturer. The communication shall be conveyed by making an entry into an interoperable electronic medical records system, through an electronic prescribing technology, a pharmacy benefit management system, or a pharmacy record that is electronically accessible by the prescriber. Entry into an electronic records system as described in this Subsection (8) is presumed to provide notice to the prescriber. Otherwise, the pharmacist shall communicate the biological product dispensed to the prescriber using facsimile, telephone, electronic transmission, or other prevailing means, provided that communication shall not be required where:

(a) there is no FDA-approved interchangeable biological product for the product prescribed; **Ĥ→ [~~or~~] ←Ĥ**

(b) a refill prescription is not changed from the product dispensed on the prior filling of the prescription **Ĥ→ [~~.~~**

~~(9) The board shall maintain a link on its website to the current list of all interchangeable biological products.~~] ; or

(c) the product is paid for using cash or cash equivalent. ←Ĥ

Section 2. Section **63I-2-258** is amended to read:

63I-2-258. Repeal dates -- Title 58.